128 related articles for article (PubMed ID: 8397787)
1. Predicting cleavability of peptide sequences by HIV protease via correlation-angle approach.
Chou JJ
J Protein Chem; 1993 Jun; 12(3):291-302. PubMed ID: 8397787
[TBL] [Abstract][Full Text] [Related]
2. A vector projection approach to predicting HIV protease cleavage sites in proteins.
Chou KC; Zhang CT; Kézdy FJ
Proteins; 1993 Jun; 16(2):195-204. PubMed ID: 8332607
[TBL] [Abstract][Full Text] [Related]
3. An alternate-subsite-coupled model for predicting HIV protease cleavage sites in proteins.
Zhang CT; Chou KC
Protein Eng; 1994 Jan; 7(1):65-73. PubMed ID: 8140096
[TBL] [Abstract][Full Text] [Related]
4. Support Vector Machines for predicting HIV protease cleavage sites in protein.
Cai YD; Liu XJ; Xu XB; Chou KC
J Comput Chem; 2002 Jan; 23(2):267-74. PubMed ID: 11924738
[TBL] [Abstract][Full Text] [Related]
5. Prediction of human immunodeficiency virus protease cleavage sites in proteins.
Chou KC
Anal Biochem; 1996 Jan; 233(1):1-14. PubMed ID: 8789141
[TBL] [Abstract][Full Text] [Related]
6. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins.
Chou KC
J Biol Chem; 1993 Aug; 268(23):16938-48. PubMed ID: 8349584
[TBL] [Abstract][Full Text] [Related]
7. Studies on the specificity of HIV protease: an application of Markov chain theory.
Chou KC; Zhang CT
J Protein Chem; 1993 Dec; 12(6):709-24. PubMed ID: 8136021
[TBL] [Abstract][Full Text] [Related]
8. Artificial neural network method for predicting HIV protease cleavage sites in protein.
Cai YD; Yu H; Chou KC
J Protein Chem; 1998 Oct; 17(7):607-15. PubMed ID: 9853675
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.
Tözsér J; Bláha I; Copeland TD; Wondrak EM; Oroszlan S
FEBS Lett; 1991 Apr; 281(1-2):77-80. PubMed ID: 2015912
[TBL] [Abstract][Full Text] [Related]
10. A formulation for correlating properties of peptides and its application to predicting human immunodeficiency virus protease-cleavable sites in proteins.
Chou JJ
Biopolymers; 1993 Sep; 33(9):1405-14. PubMed ID: 8400033
[TBL] [Abstract][Full Text] [Related]
11. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.
Chou KC; Tomasselli AG; Reardon IM; Heinrikson RL
Proteins; 1996 Jan; 24(1):51-72. PubMed ID: 8628733
[TBL] [Abstract][Full Text] [Related]
12. In silico prediction of mutant HIV-1 proteases cleaving a target sequence.
Jensen JH; Willemoës M; Winther JR; De Vico L
PLoS One; 2014; 9(5):e95833. PubMed ID: 24796579
[TBL] [Abstract][Full Text] [Related]
13. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
[TBL] [Abstract][Full Text] [Related]
14. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
Quéré L; Wenger T; Schramm HJ
Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
[TBL] [Abstract][Full Text] [Related]
15. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base.
Poorman RA; Tomasselli AG; Heinrikson RL; Kézdy FJ
J Biol Chem; 1991 Aug; 266(22):14554-61. PubMed ID: 1860861
[TBL] [Abstract][Full Text] [Related]
16. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
17. Synergistic binding of inhibitors to the protease from HIV type 1.
Asante-Appiah E; Chan WW
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):113-7. PubMed ID: 8670094
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases.
De Voss JJ; Sui Z; DeCamp DL; Salto R; Babé LM; Craik CS; Ortiz de Montellano PR
J Med Chem; 1994 Mar; 37(5):665-73. PubMed ID: 8126707
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
20. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.
Mildner AM; Rothrock DJ; Leone JW; Bannow CA; Lull JM; Reardon IM; Sarcich JL; Howe WJ; Tomich CS; Smith CW
Biochemistry; 1994 Aug; 33(32):9405-13. PubMed ID: 8068616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
